74. A kit of parts according to Claim 71, wherein the chemotherapeutic agents are 5-fluorouracil and oxaliplatin.

75. The kit of parts according to Claim 70, wherein the further therapeutic agent is cyclophosphamide and the vaccine is Stimuvax.

76. A method of treating cancer comprising administering to a subject in need thereof an effective amount of an anti-PD-L1 antibody which induces antibody dependent cell-mediated cytotoxicity (ADCC).

77. The method of Claim 76 wherein the constant region of the anti-PD-L1 antibody is IgG1.

78. The method of Claim 77 wherein the anti-PD-L1 antibody is an antibody of any of Claims 19-52.

79. A method of treating cancer comprising administering to a subject in need thereof an effective amount of the composition of Claim 53.

80. The method of any of Claims 76 - 79 wherein the cancer is selected from the group consisting of: breast, lung, colon, ovarian, melanoma, bladder, kidney, liver, salivary, stomach, gliomas, thyroid, thymic, epithelial, head and neck cancers, gastric and pancreatic cancer.

81. A method of enhancing T-cell function comprising administration of an effective amount of the composition of Claim 53 to a dysfunctional T-cell.

82. A method of treating a T-cell dysfunctional disorder comprising administering a therapeutically effective amount of the composition of Claim 53 to a patient suffering from a T-cell dysfunctional disorder.

83. The method of Claim 82, wherein the T-cell dysfunctional disorder is tumor immunity.

84. The method of Claim 83, wherein the tumor immunity results from a cancer selected from the group consisting of: breast, lung, colon, ovarian, melanoma, bladder, kidney, liver, salivary, stomach, gliomas, thyroid, thymic, epithelial, head and neck cancers, gastric and pancreatic cancer.

85. The method of any of Claims 76 - 84, further comprising the administration of at least one further therapeutic agent or vaccine.

86. The method of Claim 85, wherein the further therapeutic agent is a chemotherapeutic agent.

87. The method of Claim 86, wherein the chemotherapeutic agent is gemcitabine.

88. The method of Claim 86, wherein the chemotherapeutic agent is cyclophosphamide.

89. The method of Claim 86, wherein the chemotherapeutic agents are 5-fluorouracil and oxaliplatin.

90. The method of Claim 85, wherein the further therapeutic agent is cyclophosphamide and the vaccine is Stimuvax.

91. The method of any of Claims 76 - 90, wherein the method further comprises the application of a treatment regimen selected from the group consisting of: surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, hormonal therapy, angiogenesis inhibiton and palliative care.

92. The method of Claim 91, wherein the treatment regime is radiation therapy.

74. A kit of parts according to Claim 71, wherein the chemotherapeutic agents are 5-fluorouracil and oxaliplatin.

75. The kit of parts according to Claim 70, wherein the further therapeutic agent is cyclophosphamide and the vaccine is Stimuvax.

76. Use of an effective amount of an anti-PD-L1 antibody which induces antibody dependent cell-mediated cytotoxicity (ADCC) for the manufacture of a medicament for the treatment of cancer.

77. The use of Claim 76 wherein the constant region of the anti-PD-L1 antibody is IgG1.

78. The use of Claim 77 wherein the anti-PD-L1 antibody is an antibody of any of Claims 19-52.

79. Use of an effective amount of the composition of Claim 53 for the manufacture of a medicament for the treatment of cancer.

80. The use of any of Claims 76 - 79 wherein the cancer is selected from the group consisting of: breast, lung, colon, ovarian, melanoma, bladder, kidney, liver, salivary, stomach, gliomas, thyroid, thymic, epithelial, head and neck cancers, gastric and pancreatic cancer.

81. Use of an effective amount of the composition of Claim 53 for the manufacture of a medicament for enhancing T-cell function, wherein the said composition is administered to a dysfunctional T-cell.

82. Use of the composition of Claim 53 for the manufacture of a medicament for treating a T-cell dysfunctional disorder.

83. The use of Claim 82, wherein the T-cell dysfunctional disorder is tumor immunity.

84. The use of Claim 83, wherein the tumor immunity results from a cancer selected from the group consisting of: breast, lung, colon, ovarian, melanoma, bladder, kidney, liver, salivary, stomach, gliomas, thyroid, thymic, epithelial, head and neck cancers, gastric and pancreatic cancer.

85. The use of any of Claims 76 - 84, wherein at least one further therapeutic agent or vaccine is administered.

86. The use of Claim 85, wherein the further therapeutic agent is a chemotherapeutic agent.

87. The use of Claim 86, wherein the chemotherapeutic agent is gemcitabine.

88. The use of Claim 86, wherein the chemotherapeutic agent is cyclophosphamide.

89. The use of Claim 86, wherein the chemotherapeutic agents are 5-fluorouracil and oxaliplatin.

90. The use of Claim 85, wherein the further therapeutic agent is cyclophosphamide and the vaccine is Stimuvax.

91. The use of any of Claims 76 - 90, wherein the method further comprises the application of a treatment regimen selected from the group consisting of: surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, hormonal therapy, angiogenesis inhibiton and palliative care.

92. The use of Claim 91, wherein the treatment regime is radiation therapy.